Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS
-512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin
(Hemoglobin A1c) in patients with type 2 diabetes after 24 weeks of treatment. The safety of
this treatment will also be studied.